

# Christopher M Booth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3115997/publications.pdf>

Version: 2024-02-01

23  
papers

1,898  
citations

759233

12  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3631  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality due to cancer treatment delay: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 371, m4087.	6.0	606
2	Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2335.	7.4	544
3	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 268-270.	27.6	333
4	The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 17-28.	2.5	102
5	Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 217-226.	8.1	59
6	Time to adjuvant chemotherapy and survival in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 1243-1250.	4.1	52
7	NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. <i>Hepatology</i> , 2021, 74, 3330-3344.	7.3	44
8	Coping during COVID-19: a mixed methods study of older cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 3389-3398.	2.2	27
9	Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 155, 136-144.	2.8	20
10	Older survivors of cancer in the COVID-19 pandemic: Reflections and recommendations for future care. <i>Journal of Geriatric Oncology</i> , 2021, 12, 461-466.	1.0	19
11	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019, 8, 1584-1593.	2.8	18
12	Persistent Opioid Use Among Patients with Urolithiasis: A Population based Study. <i>European Urology Focus</i> , 2020, 6, 745-751.	3.1	16
13	Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic. <i>Ecancermedicalscience</i> , 2021, 15, 1202.	1.1	11
14	Increased risk of new persistent opioid use in pediatric and young adult patients with kidney stones. <i>Canadian Urological Association Journal</i> , 2020, 14, 237-244.	0.6	10
15	Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?. <i>Cancer</i> , 2020, 126, 4087-4088.	4.1	8
16	Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment. <i>Journal of Cancer Policy</i> , 2021, 30, 100301.	1.4	8
17	Does the use of incretin-based medications increase the risk of cancer in patients with type 2 diabetes mellitus?. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 489-499.	1.9	6
18	Transforming Canada's role in global cancer control. <i>Lancet Oncology, The</i> , 2021, 22, e400-e409.	10.7	6

#	ARTICLE	IF	CITATIONS
19	Effect of centralization on complex surgical care: A population-based case study of radical cystectomy. Canadian Urological Association Journal, 2019, 14, 91-96.	0.6	4
20	Increasing burden of cirrhosis projected to 2040 in Canada: implications for prevention, screening, and management. Journal of Hepatology, 2020, 73, S45.	3.7	3
21	Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-13.	1.9	2
22	Reply to Vikas Mishra's Letter to the Editor, re: Gregory W. Hosier, Thomas McGregor, Darren Beiko, et al. Persistent Opioid Use Among Patients with Urolithiasis: A Population based Study. Eur Urol Focus. In press. <a href="https://doi.org/10.1016/j.euf.2019.08.011">https://doi.org/10.1016/j.euf.2019.08.011</a> . European Urology Focus, 2020, 7, 897.	3.1	0
23	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. Seminars in Oncology, 2020, 47, 353-354.	2.2	0